FDA Drug Safety Board To Meet Every Six Weeks
This article was originally published in The Pink Sheet Daily
Executive Summary
The board discussed FDA's recent action on fentanyl transdermal patches (J&J's Duragesic and generics) and Purdue's Palladone (hydromorphone extended-release) during a July 27 meeting, FDA's meeting summary says.